

**UNITED STATES BANKRUPTCY COURT  
SOUTHERN DISTRICT OF NEW YORK**

---

In re:	:	Chapter 11
	:	
PURDUE PHARMA L.P., <i>et al.</i> ,	:	Case No. 19-23649 (RDD)
	:	
Debtors. <sup>1</sup>	:	(Jointly Administered)
	:	

---

**NOTICE OF THIRD MONTHLY FEE STATEMENT OF JONES DAY FOR  
COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT  
OF EXPENSES INCURRED AS SPECIAL COUNSEL TO THE DEBTORS  
FOR THE PERIOD FROM JANUARY 1, 2020 THROUGH JANUARY 31, 2020**

---

<b>Name of Applicant:</b>	Jones Day
<b>Authorized to Provide Services to:</b>	Purdue Pharma L.P., <i>et al.</i>
<b>Date of Retention:</b>	December 20, 2019, <i>nunc pro tunc</i> to September 15, 2019
<b>Period for Which Compensation and Expense Reimbursement is Sought:</b>	January 1, 2020 through January 31, 2020
<b>Amount of Compensation Requested (after 13% discount):</b>	\$244,745.96
<b>Less 20% Holdback</b>	\$48,949.19
<b>Net of Holdback:</b>	\$195,796.77
<b>Amount of Expense Reimbursement Requested:</b>	\$8,156.50

---

<sup>1</sup> The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

**Total Compensation (Net of  
Holdback) and Expense  
Reimbursement Requested:**

\$203,953.27

**This is a**

X Monthly \_\_\_\_ Interim \_\_\_\_ Final Fee Statement

*[The remainder of this page has been intentionally left blank]*

In accordance with the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals*, entered on November 21, 2019 [Docket No. 529] (the “Interim Compensation Order”),<sup>2</sup> Jones Day hereby submits this third monthly fee statement (the “Third Monthly Fee Statement”), seeking compensation for services rendered and reimbursement of expenses incurred as special counsel to the Debtors, for the period from January 1, 2020 through January 31, 2020 (the “Third Monthly Fee Period”). By this Third Monthly Fee Statement, and after taking into account certain substantial voluntary discounts and reductions,<sup>3</sup> Jones Day seeks payment in the amount of \$203,953.27, which comprises (i) 80% of the total amount of compensation sought for actual and necessary services rendered during the Third Monthly Fee Period and (ii) reimbursement of 100% of actual and necessary expenses incurred in connection with such services.

### **SERVICES RENDERED AND EXPENSES INCURRED**

1. Attached hereto as **Exhibit A** is a summary of Jones Day professionals by individual, setting forth the (a) name and title of each individual who provided services during the Third Monthly Fee Period, (b) aggregate hours spent by each individual, (c) hourly billing rate for each such individual at Jones Day’s then-current billing rates, (d) amount of fees earned by each

---

<sup>2</sup> Capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Interim Compensation Order.

<sup>3</sup> The total amount sought for fees reflects (a) voluntary write offs in the amount of \$8,512.50 and (b) application of a subsequent 13% discount on all fees, pursuant to an agreed practice between Jones Day and the Debtors which was implemented prior to the Petition Date (totaling \$45,083.74 for the Third Monthly Fee Period), for an overall voluntary reduction of approximately 16%. In addition, as part of the discounted fee arrangement, Jones Day agreed to charge the Debtors the previous year’s billable rates for the periods during which services were rendered (*i.e.*, for 2020, Jones Day is using 2019 billable rates in calculating amounts due for legal services performed). The additional value attributable to application of the prior year’s billable rates is not reflected in the 16% reduction.

Jones Day professional, and (e) year of bar admission for each attorney. The blended hourly billing rate of Jones Day timekeepers during the Third Monthly Fee Period is approximately \$751.22.<sup>4</sup>

2. Attached hereto as **Exhibit B** is a summary of the services rendered and compensation sought, by project category, for the Third Monthly Fee Period.

3. Attached hereto as **Exhibit C** is a summary of expenses incurred and reimbursement sought, by expense type, for the Third Monthly Fee Period.

4. Attached hereto as **Exhibit D** are copies of Jones Day invoices for the Third Monthly Fee Period.<sup>5</sup>

#### NOTICE AND OBJECTION PROCEDURES

5. Notice of this Third Monthly Fee Statement shall be given to the following parties (collectively, the “Notice Parties”): (i) Purdue Pharma L.P., 201 Tresser Blvd, Stamford, CT 06901, Attn: Jon Lowne, Email: Jon.Lowne@pharma.com; (ii) counsel to the Debtors, Davis Polk & Wardwell LLP, 450 Lexington Avenue, New York, New York 10017, Attn: Christopher Robertson and Dylan Consla, Email: christopher.robertson@davispolk.com, dylan.consla@davispolk.com; (iii) counsel to the Committee: (a) Akin Gump Strauss Hauer & Feld LLP, One Bryant Park, Bank of America Tower, New York, NY 10036-6745, Attn: Arik Preis, Email: apreis@akingump.com and Sara L. Brauner, Email: sbrauner@akingump.com; and (b) Bayard, P.A., 600 N. King Street, Suite 400, Wilmington, DE 19801, Attn: Justin R. Alberto and Daniel N. Brogan, Email: jalberto@bayardlaw.com and dbrogan@bayardlaw.com; and (iv) the Office of the United States Trustee, U.S. Federal Office Building, 201 Varick Street, Suite 1006, New York, New York 10014, Attn: Paul K. Schwartzberg, Email: Paul.Schwartzberg@usdoj.gov.

---

<sup>4</sup> The blended rate is comprised of all Jones Day timekeepers who provided services during the Third Monthly Fee Period.

<sup>5</sup> The time records included in **Exhibit D** have been minimally redacted to protect privileged information.

6. Objections to this Third Monthly Fee Statement, if any, must be served via electronic mail upon Jones Day, 250 Vesey Street, New York, New York 10281, Attn: Anna Kordas (akordas@jonesday.com) no later than March 30, 2020 at 12:00 p.m. (prevailing Eastern Time) (the “Objection Deadline”), setting forth the nature of the objection and the specific amount of fees or expenses at issue.

7. If no objections to this Third Monthly Fee Statement are received by the Objection Deadline, the Debtors shall promptly pay Jones Day 80% of the fees and 100% of the expenses identified in this Third Monthly Fee Statement.

8. To the extent that an objection to this Third Monthly Fee Statement is received on or before the Objection Deadline, the Debtors shall withhold payment of that portion of this Third Monthly Fee Statement to which the objection is directed and promptly pay the remainder of the fees and expenses in the percentages set forth above. To the extent such an objection is not resolved, it shall be preserved and scheduled for consideration at the next interim fee application hearing.

*[The remainder of this page has been intentionally left blank]*

**NO PRIOR REQUEST**

9. No prior request for the relief sought in this Third Monthly Fee Statement has been made to this or any other court.

Dated: March 16, 2020  
New York, NY

/s/ Anna Kordas  
JONES DAY  
John J. Normile  
Anna Kordas  
250 Vesey Street  
New York, NY 10281  
Telephone: (212) 326-3939  
Facsimile: (212) 755-7306  
Email: jjnormile@jonesday.com  
akordas@jonesday.com

*Special Counsel to the Debtors and  
Debtors in Possession*

**EXHIBIT A**

**COMPENSATION BY PROFESSIONAL PERSON**

**JONES DAY**  
**PROFESSIONAL PERSON SUMMARY**  
**JANUARY 1, 2020 – JANUARY 31, 2020**

<u>NAME</u>	<u>YEAR OF ADMISSION</u>	<u>2020 RATE</u>	<u>WITH 13% DISCOUNT</u>	<u>HOURS</u>	<u>AMOUNT</u>
<b><u>PARTNER</u></b>					
Pablo D. Hendler	1995	\$1,125.00	\$978.75	6	\$6,750.00
John J. Normile	1989	\$1,225.00	\$1,065.75	131.5	\$161,087.50
Jennifer L. Swize	2002	\$1,025.00	\$891.75	2.1	\$2,152.50
<b>TOTAL PARTNER:</b>				<b>139.6</b>	<b>\$169,990.00</b>
<b><u>OF COUNSEL</u></b>					
Kelsey I. Nix	1988	\$1,125.00	\$978.75	17.9	\$20,137.50
<b>TOTAL OF COUNSEL:</b>				<b>17.9</b>	<b>\$20,137.50</b>
<b><u>ASSOCIATE</u></b>					
Marlee R. Hartenstein	2018	\$425.00	\$369.75	44.7	\$18,997.50
Ashtyn M. Hemendinger	2018	\$550.00	\$478.50	0.7	\$385.00
Anna Kordas	2014	\$750.00	\$652.50	12.4	\$9,300.00
Kevin V. McCarthy		\$605.00	\$526.35	38.1	\$23,050.50
Adam M. Nicolais	2017	\$550.00	\$478.50	36.5	\$20,075.00
Robert N. Stander	2011	\$852.00	\$741.24	4.6	\$3,919.20
<b>TOTAL ASSOCIATE:</b>				<b>137</b>	<b>\$75,727.20</b>
<b><u>LAW CLERK</u></b>					
Nathanael D. Andrews	N/A	\$475.00	\$413.25	13.4	\$6,365.00
Serena Stein	N/A	\$525.00	\$456.75	15.8	\$8,295.00
Micah Telegen	N/A	\$525.00	\$456.75	0.1	\$52.50
<b>TOTAL LAW CLERK:</b>				<b>29.3</b>	<b>\$14,712.50</b>
<b><u>PARALEGAL</u></b>					
Steven T. Johnson	N/A	\$375.00	\$326.25	2.00	\$750.00
<b>TOTAL LEGAL SUPPORT:</b>				<b>2.00</b>	<b>\$750.00</b>
<b>TOTAL:</b>				<b>325.8</b>	<b>\$281,317.20</b>



**EXHIBIT B**

**COMPENSATION BY PROJECT CATEGORY**

**JONES DAY**  
**PROJECT CATEGORY SUMMARY**  
**JANUARY 1, 2020 – JANUARY 31, 2020**

<b>Project Category</b>	<b>Total Hours</b>	<b>Total Fees</b>
Amneal Appeal	20.1	\$12,436.70
Collegium Pharmaceuticals	3.3	\$4,012.50
Intellipharmaeutics Corp.	120.6	\$108,761.00
Strategic Corporate Advice	91.8	\$89,839.50
Project Alpha	73.8	\$52,855.00
Retention Matters	16.2	\$13,412.50
<b>TOTAL</b>	<b>325.8</b>	<b>\$281,317.20</b>
<b>13% DISCOUNT</b>		<b>\$36,571.24</b>
<b>TOTAL FEES</b>		<b>\$244,745.96</b>

**EXHIBIT C**

**EXPENSE SUMMARY**  
**JANUARY 1, 2020 – JANUARY 31, 2020**

<b>Expense Category</b>	<b>Total Expenses</b>
Consultant Fees	\$7,255.89
Travel - Food	\$13.40
Travel - Hotel	\$202.27
Travel - Taxi	\$111.40
Travel – Train	\$551.00
Mailing Charges	\$22.54
<b>TOTAL</b>	<b>\$8,156.50</b>

**EXHIBIT D**

**TIME DETAIL**

IN ACCOUNT WITH

**JONES DAY**

New York  
250 Vesey Street  
New York, NY 10281-1047  
(212) 326-3939

Federal Identification Number: 34-0319085

March 16, 2020

305158-600516

Invoice: 33357028

PURDUE PHARMA L.P.  
Attention: Philip C. Strassburger, Esq.  
Vice President, General Counsel  
One Stamford Forum  
Stamford, CT 06901

For legal services rendered for the period through January 31, 2020:

Amneal IPR Appeal (376 patent)	USD	12,436.70
Less 13% Fee Discount		<u>(1,616.77)</u>
	USD	10,819.93
<b>TOTAL</b>	<b>USD</b>	<b><u><u>10,819.93</u></u></b>

Please remit payment to:

**ACH Transfer (preferred)**

Citibank, N.A.  
New York, NY  
Account Name: Jones Day  
Account No: 37026407  
ABA No: 021000089

**Wire Transfer**

Citibank, N.A.  
New York, NY  
Account Name: Jones Day  
Account No: 37026407  
ABA No: 021000089  
Swift Code: CITIUS33

PLEASE REFERENCE 305158-600516/33357028 WITH YOUR PAYMENT

~~JONES DAY~~

305158-600516

Page 2

March 16, 2020

Amneal IPR Appeal (376 patent)

Invoice: 33357028

## TIMEKEEPER DETAIL SCHEDULE

	<i>Hours</i>	<i>Rate</i>	<i>Amount</i>
PARTNER			
J L SWIZE	2.10	1,025.00	2,152.50
ASSOCIATE			
R N STANDER	4.60	852.00	3,919.20
LAW CLERK			
N D ANDREWS	<u>13.40</u>	<u>475.00</u>	<u>6,365.00</u>
<b>TOTAL</b>	<b>20.10</b>	<b>USD</b>	<b>12,436.70</b>

~~JONES DAY~~

305158-600516

Page 3

March 16, 2020

Amneal IPR Appeal (376 patent)

Invoice: 33357028

## SERVICES DETAIL SCHEDULE

<i>Date of Service</i>	<i>Timekeeper Name</i>	<i>Hours</i>
01/06/20	J L SWIZE Attention to potential cert petition, including call with client (B. Koch).	0.30
01/07/20	R N STANDER Analyze timing for submission and ruling on petition for certiorari (.70); prepare electronic communication summarizing possible timelines for decision (.60).	1.30
01/08/20	N D ANDREWS Analyze timing of Federal Circuit petitions and consideration In re Arthrex and Polaris (1.50); research, summarize forfeiture of Arthrex issue in other Federal Circuit cases and analyze merits arguments for appeal (5.00).	6.50
01/08/20	J L SWIZE Attention to potential issues for cert petition and handling of Arthrex/Appointments Clause issues and discuss Arthrex research with N. Andrews.	0.50
01/09/20	N D ANDREWS Analyze merits arguments for appeal and communicate summary of developments of Appointments Clause waiver issue to R. Stander.	0.50
01/09/20	R N STANDER Research certiorari petitions to assist with drafting a petition for certiorari.	1.00
01/09/20	J L SWIZE Attention to strategy for potential cert petition, including timing in light of ongoing Arthrex/Appointments Clause issues (.25); advise R. Stander and N. Andrews on next steps (.25); review research from N. Andrews regarding Arthrex/Appointments Clause challenges (.50).	1.00
01/10/20	N D ANDREWS Analyze, review merits arguments for appeal.	3.50
01/13/20	J L SWIZE Review Appointments Clause-related matters, including arguments raised in other cases.	0.30
01/16/20	N D ANDREWS Research, analyze Appointments Clause waiver issue in re Arthrex.	2.90
01/16/20	R N STANDER Review Arthrex decision and analyze potential avenues for obtaining relief at the certiorari stage based on Arthrex.	2.30
<b>TOTAL</b>		<b>20.10</b>

IN ACCOUNT WITH

**JONES DAY**

**New York**  
250 Vesey Street  
New York, NY 10281-1047  
**(212) 326-3939**

Federal Identification Number: 34-0319085

March 16, 2020

305158-610005

Invoice: 33357030

PURDUE PHARMA L.P.  
Attention: Philip C. Strassburger, Esq.  
Vice President, General Counsel  
One Stamford Forum  
Stamford, CT 06901

For legal services rendered for the period through January 31, 2020:

Purdue Pharma L.P., et al v. Collegium Pharmaceuticals	USD	4,012.50
Less 13% Fee Discount		<u>(521.62)</u>
	USD	3,490.88
<b>TOTAL</b>	<b>USD</b>	<b><u><u>3,490.88</u></u></b>

Please remit payment to:

**ACH Transfer (preferred)**

Citibank, N.A.  
New York, NY  
Account Name: Jones Day  
Account No: 37026407  
ABA No: 021000089

**Wire Transfer**

Citibank, N.A.  
New York, NY  
Account Name: Jones Day  
Account No: 37026407  
ABA No: 021000089  
Swift Code: CITIUS33

PLEASE REFERENCE 305158-610005/33357030 WITH YOUR PAYMENT



Page 17 of 37  
JONES DAY

305158-610005

Page 2

March 16, 2020

Purdue Pharma L.P., et al v. Collegium Pharmaceuticals

Invoice: 33357030

## TIMEKEEPER DETAIL SCHEDULE

	<i>Hours</i>	<i>Rate</i>	<i>Amount</i>
PARTNER			
P D HENDLER	0.30	1,125.00	337.50
J J NORMILE	3.00	1,225.00	3,675.00
			<hr/>
<b>TOTAL</b>	<b>3.30</b>	<b>USD</b>	<b>4,012.50</b>

~~JONES DAY~~

305158-610005

Page 3

March 16, 2020

Purdue Pharma L.P., et al v. Collegium Pharmaceuticals

Invoice: 33357030

## SERVICES DETAIL SCHEDULE

<i>Date of Service</i>	<i>Timekeeper Name</i>	<i>Hours</i>
01/21/20	J J NORMILE Review of legal research regarding strategy regarding status of litigation.	1.50
01/22/20	J J NORMILE Continued review of legal research regarding strategy regarding status of litigation.	1.50
01/28/20	P D HENDLER Preparation for, participation in and attention to teleconference with client, including B. Koch and R. Inz, regarding status of matter and strategy regarding status of litigation.	0.30
<b>TOTAL</b>		<b>3.30</b>

IN ACCOUNT WITH

**JONES DAY**

New York  
250 Vesey Street  
New York, NY 10281-1047  
(212) 326-3939

Federal Identification Number: 34-0319085

March 16, 2020

305158-610027

Invoice: 33357114

PURDUE PHARMA L.P.  
Attention: Philip C. Strassburger, Esq.  
Vice President, General Counsel  
One Stamford Forum  
Stamford, CT 06901

For legal services rendered for the period through January 31, 2020:

Project Alpha	USD	52,855.00
Less 13% Fee Discount		<u>(6,871.15)</u>
	USD	45,983.85
<b>TOTAL</b>	<b>USD</b>	<b><u>45,983.85</u></b>

Please remit payment to:

**ACH Transfer (preferred)**

Citibank, N.A.  
New York, NY  
Account Name: Jones Day  
Account No: 37026407  
ABA No: 021000089

**Wire Transfer**

Citibank, N.A.  
New York, NY  
Account Name: Jones Day  
Account No: 37026407  
ABA No: 021000089  
Swift Code: CITIUS33

PLEASE REFERENCE 305158-610027/33357114 WITH YOUR PAYMENT

Page 2 of 37  
JONES DAY

305158-610027

Page 2

March 16, 2020

Project Alpha

Invoice: 33357114

## TIMEKEEPER DETAIL SCHEDULE

	<i>Hours</i>	<i>Rate</i>	<i>Amount</i>
PARTNER			
J J NORMILE	11.20	1,225.00	13,720.00
OF COUNSEL			
K I NIX	17.90	1,125.00	20,137.50
ASSOCIATE			
M R HARTENSTEIN	44.70	425.00	18,997.50
<b>TOTAL</b>	<b>73.80</b>	<b>USD</b>	<b>52,855.00</b>

305158-610027

Page 3

March 16, 2020

Project Alpha

Invoice: 33357114

## SERVICES DETAIL SCHEDULE

<i>Date of Service</i>	<i>Timekeeper Name</i>	<i>Hours</i>
01/05/20	K I NIX Prepared email to J. Normile regarding various procedural issues relating [REDACTED] [REDACTED]	0.80
01/06/20	J J NORMILE Review background materials relating to Project Alpha including relevant factual and legal research (2.0); review correspondence from B. Koch regarding same (.20).	2.20
01/08/20	M R HARTENSTEIN Research case law regarding various procedural issues re [REDACTED] [REDACTED] to assess likelihood of success.	2.00
01/08/20	K I NIX Conferred with J. Normile and M. Hartenstein regarding [REDACTED] [REDACTED]	1.20
01/09/20	M R HARTENSTEIN Research case law regarding [REDACTED] (.70); research standard for motions in bankruptcy court in relevant jurisdictions (3.50); prepare correspondence to K. Nix outlining same (.80).	5.00
01/09/20	K I NIX Work regarding [REDACTED] and conferred with M. Hartenstein regarding same.	1.00
01/10/20	M R HARTENSTEIN Research case law regarding [REDACTED] (3.20); research case law regarding [REDACTED] (2.10); prepare correspondence to K. Nix outlining same (.90).	6.20
01/10/20	K I NIX Work regarding [REDACTED], including conferred with M. Hartenstein.	2.20
01/13/20	M R HARTENSTEIN Research case law regarding [REDACTED] (1.50); research case law regarding [REDACTED] (2.90); research discovery rules in bankruptcy court (1.30); prepare correspondence to K. Nix outlining same (.70).	6.40
01/13/20	K I NIX Work regarding [REDACTED] and studied cases from M. Hartenstein.	2.00
01/14/20	K I NIX Studied cases and conferred with M. Hartenstein (1.00); outlined summary of research and conclusions (1.80).	2.80
01/15/20	M R HARTENSTEIN Draft memorandum analyzing [REDACTED] [REDACTED] [REDACTED] [REDACTED]	5.20
01/15/20	K I NIX Conferred with M. Hartenstein regarding [REDACTED] and studied cases and worked on draft summary memo regarding same.	2.00

JONES DAY  
Pg. 22 of 37

305158-610027

Page 4

March 16, 2020

Project Alpha

Invoice: 33357114

<i>Date of Service</i>	<i>Timekeeper Name</i>	<i>Hours</i>
01/16/20	M R HARTENSTEIN	3.50
	Revise memorandum analyzing [REDACTED] [REDACTED]	
01/16/20	K I NIX	2.30
	Conferred with M. Hartenstein regarding [REDACTED] [REDACTED] draft summary memo regarding same (2.00); conferred with J. Normile (.30).	
01/17/20	K I NIX	1.40
	Worked on summary and email to J. Normile regarding [REDACTED] [REDACTED]	
01/17/20	J J NORMILE	1.50
	Review results of legal research regarding [REDACTED]	
01/21/20	K I NIX	1.20
	Conferred with J. Normile regarding [REDACTED].	
01/22/20	J J NORMILE	2.50
	Review of various background materials relating to [REDACTED] [REDACTED]	
01/24/20	K I NIX	1.00
	[REDACTED]	
01/24/20	J J NORMILE	1.50
	Review of various background materials relating to [REDACTED] [REDACTED]	
01/29/20	M R HARTENSTEIN	5.60
	Research [REDACTED] (2.30); research recent cases in the Federal Circuit [REDACTED] (1.50); research recent cases to [REDACTED] (1.80).	
01/29/20	J J NORMILE	2.00
	Attention to [REDACTED] on various procedural issues.	
01/30/20	M R HARTENSTEIN	3.90
	Legal research regarding various venue issues.	
01/31/20	M R HARTENSTEIN	6.90
	Draft memorandum analyzing current venue standards for patent infringement cases and applicability of TC Heartland to cases that pre-date the decision.	
01/31/20	J J NORMILE	1.50
	Continued review of legal analysis on [REDACTED] motions.	
	<b>TOTAL</b>	<b>73.80</b>

IN ACCOUNT WITH

**JONES DAY**

New York  
250 Vesey Street  
New York, NY 10281-1047  
(212) 326-3939

Federal Identification Number: 34-0319085

March 16, 2020

305158-640002

Invoice: 33357115

PURDUE PHARMA L.P.  
Attention: Philip C. Strassburger, Esq.  
Vice President, General Counsel  
One Stamford Forum  
Stamford, CT 06901

For legal services rendered for the period through January 31, 2020:

Strategic Corporate Advice	USD	89,839.50
Less 13% Fee Discount		<u>(11,679.13)</u>
	USD	78,160.37
<b>TOTAL</b>	<b>USD</b>	<b><u><u>78,160.37</u></u></b>

Please remit payment to:

**ACH Transfer (preferred)**

Citibank, N.A.  
New York, NY  
Account Name: Jones Day  
Account No: 37026407  
ABA No: 021000089

**Wire Transfer**

Citibank, N.A.  
New York, NY  
Account Name: Jones Day  
Account No: 37026407  
ABA No: 021000089  
Swift Code: CITIUS33

PLEASE REFERENCE 305158-640002/33357115 WITH YOUR PAYMENT

~~JONES DAY~~

305158-640002

Page 2

March 16, 2020

Strategic Corporate Advice

Invoice: 33357115

## TIMEKEEPER DETAIL SCHEDULE

	<i>Hours</i>	<i>Rate</i>	<i>Amount</i>
PARTNER			
J J NORMILE	57.00	1,225.00	69,825.00
ASSOCIATE			
K MCCARTHY	15.90	605.00	9,619.50
A M NICOLAIS	18.90	550.00	10,395.00
<b>TOTAL</b>	<b>91.80</b>	<b>USD</b>	<b>89,839.50</b>



~~JONES DAY~~

305158-640002

Page 3

March 16, 2020

Strategic Corporate Advice

Invoice: 33357115

## SERVICES DETAIL SCHEDULE

<i>Date of Service</i>	<i>Timekeeper Name</i>	<i>Hours</i>
01/04/20	J J NORMILE Review of materials forwarded by P. Strassburger and R. Inz regarding various corporate assets including patents, patent applications and assignments (3.00); review background materials regarding potential motion (1.00).	4.00
01/05/20	J J NORMILE Continued review of materials relating to patents and clinical data trials relating to various corporate assets.	2.00
01/06/20	A M NICOLAIS Edits/revisions to weekly calendar update (.50); communication with J. Normile re same (.25); reviewing appeal's court docket re same (.50); Purdue weekly teleconference (.75); drafting AdCom meeting anticipated issues summary (2.30).	4.30
01/07/20	J J NORMILE Preparation for and participation in teleconference with P. Strassburger, B. Koch, R. Kreppel (all Purdue), E. Vonnegut and C. Robertson (both DPW) regarding various licensing issues (2.00); review background materials and prepare correspondence regarding same (.50); review correspondence regarding Kashiv letter regarding paragraph IV certification (.50).	3.00
01/08/20	J J NORMILE Continued review of various licensing issues regarding various assets including OxyContin and Hysingla.	2.50
01/09/20	J J NORMILE Attention to various issues relating to ownership and assignment of various patents relating to OxyContin including review of background materials.	3.00
01/10/20	J J NORMILE Attention to various issues relating to ownership and assignment of various patents relating to OxyContin including review of background materials.	3.50
01/12/20	K MCCARTHY Review materials related to various agreements and communicate internally with J. Normile and A. Nicolais regarding same (3.50); draft/revise summary of key agreements (1.00); perform legal research re: same (.50).	5.00
01/12/20	A M NICOLAIS Communication in firm with K. McCarthy regarding Purdue know how (.50); review/analyze assignments and agreements regarding same (2.20).	2.70
01/12/20	J J NORMILE Review background materials relating to development of various corporate products (4.00); various teleconferences with P. Strassburger, K. McCarthy and A. Nicolais regarding same (1.50).	5.50
01/13/20	K MCCARTHY Review materials related to various agreements and communicate internally with J. Normile and A. Nicolais regarding same (2.90); draft/revise memorandum regarding Purdue's potential ownership rights and communicate internally with J. Normile and A. Nicolais regarding same (4.60); perform legal research re: implied licenses (.40).	7.90
01/13/20	A M NICOLAIS Continue review/analysis of various Purdue agreements (3.20); communication in firm with J. Normile and K. McCarthy re same (2.00); drafting memorandum regarding same (4.00); weekly Purdue status call (.50).	9.70
01/13/20	J J NORMILE Review background materials relating to development of various corporate assets and review correspondence from R. Inz (including attachments) regarding same (5.00); various teleconferences with P. Strassburger, K. McCarthy and A. Nicolais regarding same (1.50); office conferences with K. McCarthy and A. Nicolais regarding same (1.00).	7.50

Page 26 of 37  
JONES DAY

305158-640002

Page 4

March 16, 2020

Strategic Corporate Advice

Invoice: 33357115

<i>Date of Service</i>	<i>Timekeeper Name</i>	<i>Hours</i>
01/14/20	K MCCARTHY	1.00
	Communicate internally with J. Normile and A. Nicolais re: memorandum concerning Purdue's potential ownership rights of certain know how (.50); draft/revise proposed list of questions concerning various corporate assets and communicate internally with J. Normile and A. Nicolais re: same (.50).	
01/14/20	A M NICOLAIS	1.80
	Drafting inquiries regarding various corporate assets (1.30); meeting with J. Normile re same (.50).	
01/14/20	J J NORMILE	1.50
	Review of due diligence sheet regarding ownership of various Purdue assets including related review of background materials.	
01/15/20	A M NICOLAIS	0.40
	Edits/revisions to Purdue patents-in-suit sheet regarding patent ownership.	
01/16/20	J J NORMILE	5.00
	Preparation for and participation in teleconference with D. Forrester (DPW), R. Inz (Purdue) and B. Koch (Purdue) regarding various OxyContin patent assets including review of various background materials (2.00) preparation for and participation in teleconferences with P. Strassburger (Purdue), R. Kreppel (Purdue) and DPW regarding various OxyContin licensing matters and review of background materials regarding same (3.00).	
01/17/20	J J NORMILE	1.50
	Review email from D. Forester (DPW) regarding various Purdue employment agreements and impact on various corporate assets.	
01/20/20	J J NORMILE	0.70
	Review email from P. Strassburger regarding CP petition to FDA on complex drugs (.50); review emails from R. Inz regarding Special Committee meeting (.20).	
01/21/20	J J NORMILE	2.00
	Continued review of various agreements relating to OxyContin (1.50); related teleconference with R. Inz (Purdue) (.50).	
01/22/20	J J NORMILE	2.80
	Continued review of various agreements relating to OxyContin (1.50); related teleconference with R. Inz (Purdue) (.50); review emails from R. Inz regarding Confidential Information Agreements (.80).	
01/24/20	J J NORMILE	2.00
	Review and revise draft memo relating to various licensing considerations including review of background materials and office conference with K. McCarthy (JD).	
01/26/20	K MCCARTHY	0.50
	Revise memorandum re: various procedural issues and communicate internally re: follow-up legal research.	
01/26/20	J J NORMILE	2.50
	Review recent correspondence relating to various corporate assets and ownership status of same and background materials (1.50); review correspondence regarding amendment to various Purdue OxyContin license agreements (1.00).	
01/27/20	K MCCARTHY	1.50
	Review legal research re: various standing issues (.70), revise memorandum re: same (.80).	
01/27/20	J J NORMILE	3.00
	Review and revision of draft legal memorandum relating to various Purdue license agreements covering OxyContin and potential amendment of same (2.50); review recent correspondence regarding same (.50).	
01/30/20	J J NORMILE	2.00
	Review of proposed amendments to various Purdue OxyContin license agreements including comments by R. Kreppel and R. Inz including review of relevant background materials.	

~~JONES DAY~~

305158-640002

Page 5

March 16, 2020

Strategic Corporate Advice

Invoice: 33357115

<i>Date of Service</i>	<i>Timekeeper Name</i>	<i>Hours</i>
01/31/20	J J NORMILE	3.00
	Preparation for and participation in multiple teleconferences with P. Strassburger, R. Kreppel, R. Inz and R. Geise regarding various amendments to Purdue's OxyContin license agreements and review of various comments regarding same and related background materials.	

**TOTAL****91.80**

IN ACCOUNT WITH

**JONES DAY**

New York  
250 Vesey Street  
New York, NY 10281-1047  
(212) 326-3939

Federal Identification Number: 34-0319085

March 16, 2020

305158-999007

Invoice: 33357117

PURDUE PHARMA L.P.  
Attention: Philip C. Strassburger, Esq.  
Vice President, General Counsel  
One Stamford Forum  
Stamford, CT 06901

For legal services rendered for the period through January 31, 2020:

Retention Matters	USD	13,412.50
Less 13% Fee Discount		<u>(1,743.62)</u>
	USD	11,668.88
<b>TOTAL</b>	<b>USD</b>	<b><u>11,668.88</u></b>

Please remit payment to:

**ACH Transfer (preferred)**

Citibank, N.A.  
New York, NY  
Account Name: Jones Day  
Account No: 37026407  
ABA No: 021000089

**Wire Transfer**

Citibank, N.A.  
New York, NY  
Account Name: Jones Day  
Account No: 37026407  
ABA No: 021000089  
Swift Code: CITIUS33

PLEASE REFERENCE 305158-999007/33357117 WITH YOUR PAYMENT

Pg 29 of 37  
JONES DAY

305158-999007

Page 2

March 16, 2020

Retention Matters

Invoice: 33357117

## TIMEKEEPER DETAIL SCHEDULE

	<i>Hours</i>	<i>Rate</i>	<i>Amount</i>
PARTNER			
J J NORMILE	3.00	1,225.00	3,675.00
ASSOCIATE			
A M HEMENDINGER	0.70	550.00	385.00
A KORDAS	12.40	750.00	9,300.00
MI TELEGEN	0.10	525.00	52.50
<b>TOTAL</b>	<b>16.20</b>	<b>USD</b>	<b>13,412.50</b>

305158-999007

Page 3

March 16, 2020

Retention Matters

Invoice: 33357117

SERVICES DETAIL SCHEDULE

<i>Date of Service</i>	<i>Timekeeper Name</i>	<i>Hours</i>
01/07/20	J J NORMILE Attention to fee retention issues including invoices for September-November 2019.	1.00
01/08/20	A M HEMENDINGER Draft/revise fee statement.	0.70
01/08/20	A KORDAS Confer with J. Normile regarding fee statement (.30); confer with A. Hemendinger regarding same (.10); review draft statement (.30).	0.70
01/08/20	M I TELEGEN Communicate w. A Hemendinger regarding fee statement.	0.10
01/20/20	A KORDAS Draft/revise monthly fee statement.	1.80
01/23/20	A KORDAS Draft/revise monthly fee statement (1.40); prepare fee statement worksheet in connection with same (1.80).	3.20
01/23/20	J J NORMILE Attention to preparation of Jones Day Fee Statement for 9/15/19 to 11/30/19.	1.00
01/24/20	A KORDAS Finalize draft of monthly fee statement (1.30); correspond with J. Normile and J. McCarthy regarding matter (.30).	1.60
01/29/20	A KORDAS Finalize first monthly fee statement (.70); confer with J. Normile regarding same (.30); coordinate filing and service of same (.50); review/revise December invoices for UST guidelines compliance (1.30); confer with J. Normile and J. McCarthy regarding same (.20).	3.00
01/29/20	J J NORMILE Various office and teleconferences with A. Kordas regarding Purdue's interim fee application for September-November 2019.	1.00
01/30/20	A KORDAS Draft/revise December monthly fee statement and supporting worksheet (1.90); correspond with J. McCarthy and J. Normile regarding same (.20).	2.10
<b>TOTAL</b>		<b>16.20</b>

IN ACCOUNT WITH

**JONES DAY**

New York  
250 Vesey Street  
New York, NY 10281-1047  
(212) 326-3939

Federal Identification Number: 34-0319085

March 16, 2020

305158-610013

Invoice: 33357202

PURDUE PHARMA L.P.  
Attention: Philip C. Strassburger, Esq.  
Vice President, General Counsel  
One Stamford Forum  
Stamford, CT 06901

For legal services rendered for the period through January 31, 2020:

Purdue Pharma L.P. et al. v. Intellipharmaeueutics Corp.	USD	108,761.00
Less 13% Fee Discount		<u>(14,138.93)</u>
	USD	94,622.07

**DISBURSEMENTS & CHARGES**

Consultants and Agents Fees	7,255.89	
Travel - Food and Beverage Expenses	13.40	
Travel - Hotel Charges	202.27	
Travel - Taxi Charges	111.40	
Travel - Train Fare	551.00	
United Parcel Service Charges	<u>22.54</u>	
		<u>8,156.50</u> **
<b>TOTAL</b>	<b>USD</b>	<b><u>102,778.57</u></b>

Please remit payment to:

**ACH Transfer (preferred)**

Citibank, N.A.  
New York, NY  
Account Name: Jones Day  
Account No: 37026407  
ABA No: 021000089

**Wire Transfer**

Citibank, N.A.  
New York, NY  
Account Name: Jones Day  
Account No: 37026407  
ABA No: 021000089  
Swift Code: CITIUS33

PLEASE REFERENCE 305158-610013/33357202 WITH YOUR PAYMENT

\*\* = Food, beverage and entertainment expense in accordance with I.R.C. Sect. 274(e)3, included in this amount is USD 13.40

JONES DAY

305158-610013

Page 2

March 16, 2020

Purdue Pharma L.P. et al. v. Intellipharmaeutics Corp.

Invoice: 33357202

## TIMEKEEPER DETAIL SCHEDULE

	<i>Hours</i>	<i>Rate</i>	<i>Amount</i>
PARTNER			
P D HENDLER	5.70	1,125.00	6,412.50
J J NORMILE	57.30	1,225.00	70,192.50
ASSOCIATE			
K MCCARTHY	22.20	605.00	13,431.00
A M NICOLAIS	17.60	550.00	9,680.00
LAW CLERK			
S R STEIN	15.80	525.00	8,295.00
PARALEGAL			
S T JOHNSON	<u>2.00</u>	375.00	<u>750.00</u>
<b>TOTAL</b>	<b>120.60</b>	<b>USD</b>	<b>108,761.00</b>



Pg 33 of 37  
JONES DAY

305158-610013

Page 3

March 16, 2020

Purdue Pharma L.P. et al. v. Intellipharmaeueutics Corp.

Invoice: 33357202

## SERVICES DETAIL SCHEDULE

<i>Date of Service</i>	<i>Timekeeper Name</i>	<i>Hours</i>
01/02/20	J J NORMILE	4.50
	Preparation for and participation in teleconference with P. Strassburger and B. Koch regarding upcoming FDA AdCom meeting and preparation for same (1.50); attention to legal research regarding timeline for IPC I trial (.50); review background materials regarding potential amendment to Purdue OxyContin license (1.00); teleconference with P. Strassburger and B. Koch regarding timing of IPC and Collegium actions and review background materials regarding same (1.50).	
01/03/20	J J NORMILE	4.00
	Continued research regarding potential trial dates before Judge Andrews and impact of upcoming FDA AdCom meeting (1.50); attention to various issues regarding litigation strategy (2.50).	
01/06/20	K MCCARTHY	0.50
	Participate in client teleconference regarding weekly litigation status updates with J. Normile and A. Nicolais (0.50).	
01/06/20	J J NORMILE	4.00
	Preparation for and participation in weekly status teleconference with P. Strassburger, R. Kreppel, B. Koch, R. Inz, R. Silbert, K. McCarthy and A. Nicolais regarding various outstanding issues including IPC NDA and upcoming AdCom meeting (2.5); review background materials for AdCom meeting and emails from P. Mathers and R. Mannion (1.5).	
01/07/20	A M NICOLAIS	2.70
	Continue drafting AdCom meeting anticipated agenda (1.30); reviewing IPC re-submission NDA re same (1.40).	
01/07/20	J J NORMILE	2.00
	Review correspondence from R. Mannion, R. Fanelli and P. Strassburger regarding upcoming AdCom meeting (.50); review background materials regarding same (1.5).	
01/08/20	J J NORMILE	2.50
	Review various materials in preparation for upcoming AdCom meeting.	
01/09/20	K MCCARTHY	0.50
	Draft/revise summary of potential issues to be discussed at IPC's upcoming FDA Adcom Meeting and communicate internally with A. Nicolais and J. Normile regarding same (0.50).	
01/09/20	A M NICOLAIS	2.20
	Draft/revise summary of anticipated topics of IPC AdCom meeting for J. Normile (2.00); communication in firm with K. McCarthy re same (.20).	
01/09/20	J J NORMILE	2.00
	Continued review of relevant materials for upcoming IPC AdCom meeting.	
01/10/20	J J NORMILE	2.50
	Continued review of relevant materials for upcoming IPC AdCom meeting.	
01/13/20	P D HENDLER	0.50
	Preparation for, participation in and attention to teleconference with client (including P. Strassburger) regarding upcoming AdCom meeting.	
01/13/20	K MCCARTHY	0.60
	Client teleconference with J. Normile, P. Hendler, and A. Nicolais re: Purdue weekly litigation status updates and FDA briefing packet for upcoming IPC AdCom meeting.	
01/13/20	J J NORMILE	2.50
	Preparation for and participation in weekly call with P. Strassburger, R. Silbert, R. Inz, B. Koch, R. Kreppel, P. Hendler, K. McCarthy regarding status of proceedings (1.5); review AdCom materials (1.0).	

JONES DAY

305158-610013

Page 4

March 16, 2020

Purdue Pharma L.P. et al. v. Intellipharmaeueutics Corp.

Invoice: 33357202

<i>Date of Service</i>	<i>Timekeeper Name</i>	<i>Hours</i>
01/14/20	P D HENDLER	1.40
	Attention to various underlying factual issues and teleconferences with client (F. Hutchinson; B. Koch) regarding same.	
01/14/20	S T JOHNSON	0.50
	Search for and assemble relevant expert reports and supporting documents for reference by attorneys.	
01/14/20	J J NORMILE	7.00
	Review FDA and IPC briefing materials for upcoming AdCom meeting and related background materials (3.0); review memorandum and related materials regarding AdCom Committee (1.0); related conferences with P. Strassburger (Purdue) and B. Koch (Purdue) regarding same (1.0); travel to Silver Spring, MD regarding same (2.0).	
01/15/20	J J NORMILE	7.00
	Preparation for and attendance at FDA AdCom meeting on IPC's NDA including various emails from P. Strassburger (Purdue) and R. Fanelli (Purdue) with attached background materials from Pink Sheets (6.0); related conferences with Messrs. Strassburger, Koch and Inz (1.0).	
01/16/20	P D HENDLER	1.50
	Attention to various underlying factual issues.	
01/16/20	J J NORMILE	2.50
	Various office and teleconferences regarding results of IPC AdCom meeting with P. Strassburger, R. Silbert, R. Inz, R. Kreppel and B. Koch, including review of various press releases.	
01/17/20	P D HENDLER	1.50
	Attention to testimony for purposes of review regarding infringement claims.	
01/17/20	S T JOHNSON	1.50
	Search archives from past closed but relevant litigations for key expert materials for reference by attorneys.	
01/17/20	K MCCARTHY	2.00
	Review IPC AdCom meeting materials and communicate internally with J. Normile and A. Nicolais regarding IPC's AdCom meeting and follow-up legal research (1.00); perform legal research regarding results of AdCom meeting (1.00).	
01/17/20	A M NICOLAIS	2.10
	Meeting with J. Normile re IPC AdCom meeting (.20); legal research regarding various procedural issues (1.60); communication with K. McCarthy regarding same (.30).	
01/17/20	J J NORMILE	1.00
	Review correspondence and attached materials from P. Strassburger regarding AdCom meeting.	
01/18/20	A M NICOLAIS	4.00
	Research regarding various procedural issues (3.00); drafting summary regarding same (1.00).	
01/18/20	J J NORMILE	2.00
	Review legal research regarding procedural issues of pending litigation matters in view of AdCom meeting (1.5); review email from R. Mannion (technical expert).	
01/19/20	K MCCARTHY	0.60
	Review legal research and draft/revise internal email summary regarding various procedural issues.	
01/19/20	J J NORMILE	2.00
	Continued review of legal research regarding procedural issues impacting pending litigation in view of IPC AdCom meeting including various emails from K. McCarthy (JD).	
01/20/20	K MCCARTHY	3.00
	Review legal research and draft/revise memo regarding various procedural issues (2.50); communicate with J. Normile regarding follow-up legal research requests (.50).	

305158-610013

Page 5

March 16, 2020

Purdue Pharma L.P. et al. v. Intellipharmaeueutics Corp.

Invoice: 33357202

<i>Date of Service</i>	<i>Timekeeper Name</i>	<i>Hours</i>
01/20/20	A M NICOLAIS Draft/revise memo regarding various procedural issues.	2.00
01/20/20	J J NORMILE Preparation for and participation in weekly status teleconference with Purdue team (P. Strassburger, R. Silbert, R. Inz, R. Kreppel and B. Koch) (1.0); review legal research regarding various procedural issues in view of results of AdCom meeting (1.0).	2.00
01/20/20	S R STEIN Communicate with K. McCarthy regarding research for memo (.50); draft case law summaries dealing with various procedural issues and review and analyze regarding same (4.50).	5.00
01/21/20	K MCCARTHY Review legal research and updated memo re: various procedural issues and communicate with A. Nicolais re: same.	0.50
01/21/20	A M NICOLAIS Drafting memorandum regarding various procedural issues.	2.20
01/21/20	S R STEIN Review and analyze case law dealing with various procedural issues (2.00); draft summaries regarding same (.40).	3.90
01/22/20	K MCCARTHY Review legal research regarding various procedural issues and communicate internally with A. Nicolais and S. Stein re: same (1.50); review, revise, and provide comments to memorandum and communicate with A. Nicolais and S. Stein re: same (3.00).	4.50
01/22/20	A M NICOLAIS Team meeting re varius procedural issues memorandum (.50); edits/revisions to same (1.00).	1.50
01/22/20	S R STEIN Review and analyze draft of memorandum regarding various procedural issues (2.00); communicate with K. McCarthy and A. Nicolais regarding same (.40).	2.40
01/23/20	K MCCARTHY Draft/revise memorandum re: various procedural issues and communicate with A. Nicolais and S. Stein re: same (3.00); communicate with J. Normile re: comments to draft memorandum and required follow up research (.50); perform legal research re: same (.50).	4.00
01/23/20	J J NORMILE Review and revision of draft memorandum regarding various procedural issues relating to viability of IPC NDA product (3.00); related office conference with K. McCarthy (JD) (.50); review background materials (.80).	4.30
01/24/20	K MCCARTHY Perform legal research re: procedural issues, and communicate internally with J. Normile re: same (3.50); revise memorandum to incorporate new legal research and communicate internally with A. Nicolais and S. Stein re: same (2.50).	6.00
01/24/20	A M NICOLAIS Review/edit IPC procedural issues memorandum.	0.90
01/24/20	J J NORMILE Review and revision of draft memo relating to procedural issues relating to IPC's NDA in view of AdCom meeting including review of relevant Federal Circuit jurisprudence (2.0); related office and teleconferences with K. McCarthy (JD) (1.0).	3.00
01/24/20	S R STEIN Review and analyze cited cases and statutes in memorandum regarding jurisdictional issues (.50); communicate with K. McCarthy and A. Nicolais regarding same (.30).	0.80

**JONES DAY**

305158-610013

Page 6

March 16, 2020

Purdue Pharma L.P. et al. v. Intellipharmaeueutics Corp.

Invoice: 33357202

<i>Date of Service</i>	<i>Timekeeper Name</i>	<i>Hours</i>
01/26/20	S R STEIN	2.70
	Research regarding structuring issues and communicate with K. McCarthy regarding same.	
01/27/20	P D HENDLER	0.50
	Consideration of strategy regarding status of IPC's NDA and law regarding same.	
01/27/20	S R STEIN	1.00
	Review and analyze case law regarding structuring issues and revise memo regarding same.	
01/28/20	P D HENDLER	0.30
	Preparation for, participation in and attention to teleconference with client, including B. Koch and R. Inz, regarding status of matter and strategy regarding IPC's AdComm meeting and NDA.	
01/28/20	J J NORMLE	2.50
	Preparation for and participation in team teleconference with B. Koch and R. Inz regarding various outstanding litigation matters including Collegium and IPC (1.50); review research memoranda regarding same (1.00).	
<b>TOTAL</b>		<b>120.60</b>

Pg 37 of 37  
JONES DAY

305158-610013

Page 7

March 16, 2020

Purdue Pharma L.P. et al. v. Intellipharmaeueutics Corp.

Invoice: 33357202

## DISBURSEMENT DETAIL

<i>Date</i>	<i>Timekeeper Name</i>	<i>Location</i>	<i>Amount</i>	<i>Total</i>
<b>CONSULTANTS FEES</b>				
01/14/20	NYC ACCOUNTING	NYC	1,500.00	
Consultants fees - EMERSON RESOURCES, INC. for December 2019 storage (Invoice 22725 12/31/2019).				
01/29/20	NYC ACCOUNTING	NYC	5,755.89	
Consultants fees - MANNION CONSULTING LLC (Richard O. Mannion) for professional services rendered - January 2020 (Invoice 1061 2/02/2020).				
<b>Consultants fees Subtotal</b>				<b>7,255.89</b>
<b>FOOD AND BEVERAGE EXPENSES</b>				
01/23/20	J J NORMILE	NYC	3.86	
Food and beverage expenses other re: travel to Silver Spring, MD for FDA Advisory Committee Meeting 14-Jan-2020 John Normile				
01/23/20	J J NORMILE	NYC	9.54	
Food and beverage expenses: breakfast re: travel to Silver Spring, MD for FDA Advisory Committee Meeting 15-Jan-2020				
<b>Food and beverage expenses Subtotal</b>				<b>13.40</b>
<b>HOTEL CHARGES</b>				
01/23/20	J J NORMILE	NYC	202.27	
Hotel charges - to attend FDA Advisory Committee Meeting in Silver Spring, MD on IPC's NDA 14-Jan-2020 to 15-Jan-2020 1 night				
<b>Hotel charges Subtotal</b>				<b>202.27</b>
<b>TAXI FARE</b>				
01/23/20	J J NORMILE	NYC	34.07	
Taxi fare - Union Station to Silver Spring, MD to attend FDA Advisory Committee Meeting in Silver Spring, MD on IPC's NDA 14-Jan-2020				
01/23/20	J J NORMILE	NYC	43.39	
Taxi fare - FDA (Silver Spring) to Union Station re: travel to attend FDA Advisory Committee Meeting in Silver Spring, MD on IPC's NDA 15-Jan-2020				
01/31/20	J J NORMILE	NYC	33.94	
Taxi Fare - DIAL CAR 1/14/2020 from office to train station (Vesey St NYC to 230 W 31 St NYC10001) re: travel to FDA Advisory Committee Meeting in Silver Spring, MD.				
<b>Taxi Fare Subtotal</b>				<b>111.40</b>
<b>TRAIN FARE</b>				
01/31/20	J J NORMILE	NYC	551.00	
Train Fare - to/from Washington, D.C. - New York Penn re: attendance at FDA AdCom Mtg. 15-Jan-2020.				
<b>Train Fare Subtotal</b>				<b>551.00</b>
<b>UNITED PARCEL SERVICE CHARGES</b>				
01/17/20	J J NORMILE	NYC	22.54	
United Parcel Services Charges, John Normile, Jones Day, 1Z10445E8496886469				
<b>United Parcel Service charges Subtotal</b>				<b>22.54</b>
<b>TOTAL</b>			<b>USD</b>	<b>8,156.50</b>